Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Videos

PharmTech spoke with Elisabeth Gardiner, chief scientific officer at Tevard Biosciences, about how hands-on, early exposure to STEM fields can demystify complex concepts.

Women in STEM: Cultivating Scientific Confidence

Articles

FDA has granted priority review to AstraZeneca's Datroway for the first-line treatment of metastatic TNBC treatment.

FDA Grants Priority Review to AZ's Datroway for Metastatic Triple Negative Breast Cancer

PharmTech spoke with Dr. Stacy Lindborg, president and CEO of IMUNON, about her experience at IMUNON, which is developing a novel DNA-based approach to treat ovarian cancer.

Women Leading Biotech: Advancing Treatments for Ovarian Cancer

The companies’ “Change the Target. Change What’s Possible” targets the potential of Factor XIa inhibition in the development of treatments for thromboembolic disease.

Bristol Myers Squibb and Johnson & Johnson Launch Educational Program for Thromboembolic R&D

PharmTech spoke with Katy MacLellan, Technical Team leader, Symbiosis Pharmaceutical Services Ltd., about the women in the pharmaceutical industry that inspire her.

Women in STEM: Inspiration from Innovators in Pharma

Repertoire’s T cell receptor-epitope discovery platform will be used to develop tolerizing therapy development candidates with Eli Lilly and Company.  

Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases

, specializes in business development, new product planning, and early brand strategy. He helps companies lay the foundation for successful launches through data-backed strategies spanning indication assessment to portfolio strategy. With a strong background in pricing and market access, Nathan integrates both commercial and access insights into early asset development to maximize market opportunity.

In part one of this four-part series regarding rare diseases, the author explores how rare disease treatment development evolved from a niche area to a cornerstone of biopharma growth. 

Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine

Visit PharmTech.com for upcoming coverage of the International Day of Women and Girls in Science on February 11.

Innovations from Women in STEM 

The European Commission has approved GSK’s adjuvanted recombinant respiratory syncytial virus vaccine, Arexvy, for use in adults aged 18 years and older. 

GSK’s RSV Vaccine Approved in Europe

In a 2026 industry outlook interview, Laine Mello, Ecolab Life Sciences, explains how next-gen therapies, digitalization, and partnerships drive pharma agility.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development